Inventiva S.A. (NASDAQ:IVA) Receives Average Recommendation of “Buy” from Brokerages

Inventiva S.A. (NASDAQ:IVA) has received a consensus recommendation of “Buy” from the eight research firms that are covering the company, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $17.00.

IVA has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Inventiva in a report on Monday, April 1st. Lifesci Capital reissued an “outperform” rating on shares of Inventiva in a research report on Friday, January 5th. Canaccord Genuity Group upped their price target on Inventiva from $12.00 to $20.00 and gave the company a “buy” rating in a report on Monday, April 8th. Finally, Stifel Nicolaus dropped their price target on shares of Inventiva from $27.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, February 16th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC purchased a new stake in Inventiva in the first quarter valued at approximately $51,000. Citigroup Inc. increased its holdings in shares of Inventiva by 91.7% in the 1st quarter. Citigroup Inc. now owns 23,000 shares of the company’s stock valued at $84,000 after acquiring an additional 11,000 shares during the period. Finally, Morgan Stanley increased its holdings in shares of Inventiva by 300.0% in the 4th quarter. Morgan Stanley now owns 6,000 shares of the company’s stock valued at $27,000 after acquiring an additional 4,500 shares during the period. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Price Performance

Shares of NASDAQ:IVA opened at $3.31 on Friday. Inventiva has a 52 week low of $2.22 and a 52 week high of $5.05. The company’s 50 day moving average is $3.68 and its two-hundred day moving average is $3.93.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.